Tag: obesity drug
Study: Altimmune Obesity Drug for Alcohol Use Disorder Research
Boston's biotech sector is facing challenges, with companies struggling amid a slump in the industry. Despite hopes for a turnaround in 2025, falling stock values, layoffs, and excess lab space have left the region...
Next-Gen Obesity Drug Disappoints: Novo Nordisk Shares Drop
Novo Nordisk, a pharmaceutical giant, recently experienced a setback that sent shockwaves through the industry. The company's highly anticipated next-generation obesity drug, CagriSema, failed to meet investors' expectations, resulting in a significant drop in...
